CHILD/TEEN IMMUNIZATION SCREENING QUESTIONNAIRE

I acknowledge that I have been given a copy and have read, or have had explained to me the information in the Vaccine Information Statement(s) and have received a copy of MultiCare Health System's Notice of Privacy Practice (NPP). I have had a chance to ask questions that were answered to my satisfaction. I understand the risks and benefits of the vaccine(s). I request that the vaccine(s) indicated be given to the child/adolescent named below for whom I am the parent or legal guardian, for whom I am authorized to make this request. Lunderstand my child's immunization information is entered into an electronic database that can be shared with other providers/school personal.

		Signature		Date	
Child's Name : (First)	(Middle)	(Last)	Birth Date:	Age:	ом ог
Address:(Street Address)		(6.1)	(Chata)	Zip Code)	1 H = N
Phone: (Street Address)	Cell F	(City) Phone:		ame:	
Uninsured - No Privately Insure	Insurance  Under Insu		American On or eligible	e for State Supported Insuran ealthy Options, Molina, Basic H	
1. Is the child sick today?				Yes □ No	☐ Don't Kno
<ol><li>Does the child have allergie</li></ol>	es to medications, food, a vacci	ne component, or latex?		Yes No	□ Don't Kno
4. Does the child have a long-	term health problem with lung,	t? heart, kidney or metabolic diseas ency, a cochlear implant, or a spin	se (e.g., diabetes), asthma, a		□ Don t Kno
aspirin therapy?				Yes □ No	☐ Don't Kno
		s a healthcare provider told you th			Don't Kno
6. If your child is a baby, have	you ever been told he or she ha	as had intussusception?		□ Yes □ No	Don't Kno
7. Has the child, a sibling, or a	parent had a seizure; has the c	hild had brain or other nervous sy	stem problems?	Yes □ No	☐ Don't Kno
<ol><li>Does the child have cancer</li></ol>	, leukemia, HIV/AIDS, or any of	her immune system problem?		Yes No	☐ Don't Kno
		nune system problem? affect the immune system such as		Yes 🗆 No	☐ Don't Kno
or anticancer drugs; drugs	for the treatment of rheumatoic	d arthritis, Crohn's disease, or pso od or blood products, or been give	riasis; or had radiation treatmen		□ Don't Kno
an antiviral drug?				☐ Yes ☐ No	☐ Don't Kno
		ecome pregnant during the next			
13. Has the child received vacc					Uon t Kno
	DO NOT WRITE BEL	OW THIS LINE (Staff Only-C	Circle applicable information	on)	
ROTAVIRUS	HAEMOPHILUS (HIB)	PCV-13/ PPSV23*high risk	Circle applicable information DTaP-IPV-Hep. B	on) DTaP-IPV	
ROTAVIRUS				The state of the s	
	HAEMOPHILUS (HIB)	PCV-13/ PPSV23*high risk	DTaP-IPV-Hep. B	DTaP-IPV	
Rota Teq	HAEMOPHILUS (HIB) ActHib/Pedvax HIB	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax *	DTaP-IPV-Hep. B Pediarix	DTaP-IPV Kinrix	
ROTAVIRUS Rota Teq Mfg. Merck	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax * Mfg. Wyeth	DTaP-IPV-Hep. B Pediarix Mfg. GSK/Sanofi	DTaP-IPV Kinrix Mfg. GSK	
ROTAVIRUS Rota Teq Mfg. Merck Lot#	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot #	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax * Mfg. Wyeth Lot #	Pediarix Mfg. GSK/Sanofi Lot #	DTaP-IPV Kinrix Mfg. GSK Lot #	
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat.	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax*  Mfg. Wyeth Lot # Site: L R Vas. Lat.	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat.	Mfg. GSK Lot # Site: L R Del. Vas. Lat	
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax*  Mfg. Wyeth  Lot #  Site: L R Vas. Lat.  Dose # 0.5 mL IM	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM	Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL	
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date:	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax * Mfg. Wyeth Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date:	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date:	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date:	
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date:	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax*  Mfg. Wyeth Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date:  HEPATITIS B	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV	
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV Ipol	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax * Mfg. Wyeth Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS B Recombivax/Engerix	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad	
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV Ipol Mfg. Sanofi	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA Mfg. GSK/Merck	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax *  Mfg. Wyeth  Lot #  Site: L R Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HEPATITIS B  Recombivax/Engerix  Mfg. Merck/GSK	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II Mfg. Merck	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad Mfg. Merck	IM
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV Ipol Mfg. Sanofi Lot #	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA Mfg. GSK/Merck Lot #	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax * Mfg. Wyeth Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS B Recombivax/Engerix Mfg. Merck/GSK Lot #	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II Mfg. Merck Lot #	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad Mfg. Merck Lot #	IM eg
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV Ipol Mfg. Sanofi Lot # Site: L R Arm Leg	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA Mfg. GSK/Merck Lot # Site: L R Del. Vas. Lat.	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax*  Mfg. Wyeth  Lot #  Site: L R Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HEPATITIS B  Recombivax/Engerix  Mfg. Merck/GSK  Lot #  Site: L R Dol. Vas. Lat.	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II Mfg. Merck Lot # Site: L R Arm Lcg	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad Mfg. Merck Lot # Site: L R Arm Let	IM eg
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV Ipol Mfg. Sanofi Lot # Site: L R Arm Leg Dose# 0.5 mL SQ/IM	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA Mfg. GSK/Merck Lot # Site: L R Del. Vas. Lat. Dose# 0.5 mL IM	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax *  Mfg. Wyeth  Lot #  Site: L R Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HEPATITIS B  Recombivax/Engerix  Mfg. Merck/GSK  Lot #  Site: L R Dol. Vas. Lat.  Dose# 0.5 mL IM	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II Mfg. Merck Lot # Site: L R Arm Lcg Dose # 0.5 mL SubQ	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad Mfg. Merck Lot # Site: L R Arm Li Dose # 0.5 mL St	IM eg
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV Ipol Mfg. Sanofi Lot # Site: L R Arm Leg Dose # 0.5 mL SQ/IM VIS date:	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA Mfg. GSK/Merck Lot # Site: L R Del. Vas. Lat. Dose# 0.5 mL IM VIS date:	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax*  Mfg. Wyeth  Lot #  Site: L R Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HEPATITIS B  Recombivax/Engerix  Mfg. Merck/GSK  Lot #  Site: L R Dol. Vas. Lat.  Dose # 0.5 mL IM  VIS date:	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II Mfg. Merck Lot # Site: L R Arm Log Dose # 0.5 mL SubQ VIS date:	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad Mfg. Merck Lot # Site: L R Arm Lot Dose # 0.5 mL Site  DTAP-IPV-HIB / Marce Kinrix  Mfg. GSK Lot # Site: L R Arm Lot Lot # Site: L	eg ubQ
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV Ipol Mfg. Sanofi Lot # Site: L R Arm Leg Dose# 0.5 mL SQ/IM VIS date: DTaP /DT/ Td / Tdap/	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA Mfg. GSK/Merck Lot # Site: L R Del. Vas. Lat. Dose# 0.5 mL IM VIS date: MCV - 4	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax * Mfg. Wyeth Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS B Recombivax/Engerix Mfg. Merck/GSK Lot # Site: L R Dol. Vas. Lat. Dose # 0.5 mL IM VIS date: HPV9	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II Mfg. Merck Lot # Site: L R Arm Lcg Dose # 0.5 mL SubQ VIS date: INFLUENZA	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad Mfg. Merck Lot # Site: L R Arm Le Dose # 0.5 mL St  Pentacel / Be	eg ubQ
ROTAVIRUS  Rota Teq  Mfg. Merck  Lot#  Site: PO  Dose# 2.0 mL PO  VIS date:  IPV  Ipol  Mfg. Sanofi  Lot #  Site: L R Arm Leg  Dose # 0.5 mL SQ/IM  VIS date:  DTaP / DT / Td / Tdap/  Infanrix/DT / Tenivac/Boostrix	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA Mfg. GSK/Merck Lot # Site: L R Del. Vas. Lat. Dose# 0.5 mL IM VIS date: MCV - 4 Menactra/Meneveo	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax*  Mfg. Wyeth  Lot #  Site: L R Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HEPATITIS B  Recombivax/Engerix  Mfg. Merck/GSK  Lot #  Site: L R Dol. Vas. Lat.  Dose# 0.5 mL IM  VIS date:  HPV9  Gardasil 9	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II Mfg. Merck Lot # Site: L R Arm Lcg Dose # 0.5 mL SubQ VIS date: INFLUENZA Name:	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad Mfg. Merck Lot # Site: L R Arm Li Dose # 0.5 mL St  DTAP-IPV-HIB / M Pentacel / Bi	eg ubQ MEN B exsero
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV Ipol Mfg. Sanofi Lot # Site: L R Arm Leg Dose# 0.5 mL SQ/IM VIS date: DTaP / DT / Td / Tdap/ Infanrix/DT / Tenivac/Boostrix Mfg. Sanofi,/GSIK	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA Mfg. GSK/Merck Lot # Site: L R Del. Vas. Lat. Dose# 0.5 mL IM VIS date: MCV - 4 Menactra/Meneveo Mfg: Sanofi/Novartis	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax *  Mfg. Wyeth  Lot #  Site: L R Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HEPATITIS B  Recombivax/Engerix  Mfg. Merck/GSK  Lot #  Site: L R Dol. Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HPV9  Gardasil 9  Mfg. Merck	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II Mfg. Merck Lot # Site: L R Arm Lcg Dose # 0.5 mL SubQ VIS date: INFLUENZA Name: Mfg.:	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad Mfg. Merck Lot # Site: L R Arm Li Dose # 0.5 mL St  DTAP-IPV-HIB / M Pentacel / Be Mfg:Sanofi / G	eg ubQ MEN B exsero
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV Ipol Mfg. Sanofi Lot # Site: L R Arm Leg Dose # 0.5 mL SQ/IM VIS date: DTaP / DT / Td / Tdap/ Infanrix/DT / Tenivac / Boostrix Mfg. Sanofi, GSIK Lot #	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA Mfg. GSK/Merck Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MCV - 4 Menactra/Meneveo Mfg: Sanofi/Novartis Lot #:	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax*  Mfg. Wyeth  Lot #  Site: L R Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HEPATITIS B  Recombivax/Engerix  Mfg. Merck/GSK  Lot #  Site: L R Dol. Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HPV9  Gardasil 9  Mfg. Merck  Lot #	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II Mfg. Merck Lot # Site: L R Arm Log Dose # 0.5 mL SubQ VIS date: INFLUENZA Name: Mfg.: Lot#	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad Mfg. Merck Lot # Site: L R Arm L Dose # 0.5 mL St  DTAP-IPV-HIB / M Pentacel / Be Mfg:Sanofi / G Lot #	egbQ
ROTAVIRUS Rota Teq Mfg. Merck Lot# Site: PO Dose# 2.0 mL PO VIS date: IPV Ipol Mfg. Sanofi Lot # Site: L R Arm Leg Dose # 0.5 mL SQ/IM VIS date: DTaP /DT / Td / Tdap/ Infanrix/DT / Tenivac/Boostrix Mfg. Sanofi, /GSIK Lot # Site: L R Del. Vas. Lat.	HAEMOPHILUS (HIB) ActHib/Pedvax HIB Mfg. Sanofi/Merck Lot # Site: L R Vas. Lat. Dose # 0.5 mL IM VIS date: HEPATITIS A Havrix/VAQTA Mfg. GSK/Merck Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MCV - 4 Menactra/Meneveo Mfg: Sanofi/Novartis Lot #: Site: L R Deltoid	PCV-13/ PPSV23*high risk Prevnar/ Pneumovax*  Mfg. Wyeth  Lot #  Site: L R Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HEPATITIS B  Recombivax/Engerix  Mfg. Merck/GSK  Lot #  Site: L R Dol. Vas. Lat.  Dose # 0.5 mL IM  VIS date:  HPV9  Gardasil 9  Mfg. Merck  Lot #  Site: L R Deltoid	Pediarix Mfg. GSK/Sanofi Lot # Site: L R Del. Vas. Lat. Dose # 0.5 mL IM VIS date: MMR MMR II Mfg. Merck Lot # Site: L R Arm Leg Dose # 0.5 mL SubQ VIS date: INFLUENZA Name: Mfg.: Lot # Site: L R Del Vas. Lat. Nas.	DTaP-IPV Kinrix Mfg. GSK Lot # Site: L R Del. Vas. Lat Dosage: 0.5 mL VIS date: VARICELLA / MMRV Varivax / ProQuad Mfg. Merck Lot # Site: L R Arm L Dose # 0.5 mL St  DTAP-IPV-HIB / N Pentacel / Be Mfg:Sanofi / G Lot # Site: L R Del	egbQ

Name:

MRN #:

CSN #:

Age / Sex and Gender:

**SCREENING QUESTIONNAIRE** 

MultiCare 🔼



## Information for Healthcare Professionals about the Screening Checklist for Contraindications to Vaccines (Children and Teens)

Are you interested in knowing why we included a certain question on the screening checklist? If so, read the information below. If you want to find out even more, consult the references in **Notes** below.

NOTE: For supporting documentation on the answers given below, go to the specific ACIP vaccine recommendation found at the following website: www.cdc.gov/vaccines/hcp/acip-recs/index.html

1. Is the child sick today? [all vaccines]

There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events. However, as a precaution with moderate or severe acute illness, all vaccines should be delayed until the illness has improved. Mild illnesses (such as otitis media, upper respiratory infections, and diarrhea) are NOT contraindications to vaccination. Do not withhold vaccination if a person is taking antibiotics.

2. Does the child have allergies to medications, food, a vaccine component, or latex? [all vaccines]

An anaphylactic reaction to latex is a contraindication to vaccines that contain latex as a component or as part of the packaging (e.g., vial stoppers, prefilled syringe plungers, prefilled syringe caps). If a person has anaphylaxis after eating gelatin, do not administer vaccines containing gelatin. A local reaction to a prior vaccine dose or vaccine component, including latex, is not a contraindication to a subsequent dose or vaccine containing that component. For information on vaccines supplied in vials or syringes containing latex, see www.cdc.gov/ vaccines-pubs/pinkbook/downloads/appendices/B/latex-table.pdf; for an extensive list of vaccine components, see www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/ excipient-table-2.pdf. People with egg allergy of any severity can receive any recommended influenza vaccine (i.e., any IIV, RIV, or LAIV) that is otherwise appropriate for the patient's age and health status. For people with a history of severe allergic reaction to egg involving any symptom other than hives (e.g., angioedema, respiratory distress), or who required epinephrine or another emergency medical intervention, the vaccine should be administered in a medical setting, such as a clinic, health department, or physician office. Vaccine administration should be supervised by a healthcare provider who is able to recognize and manage severe allergic conditions.

- 3. Has the child had a serious reaction to a vaccine in the past? [all vaccines]

  History of anaphylactic reaction (see question 2) to a previous dose of vaccine or vaccine component is a contraindication for subsequent doses. History of encephalopathy within 7 days following DTP/DTaP is a contraindication for further doses of pertussis-containing vaccine. There are other adverse events that might have occurred following vaccination that constitute contraindications or precautions to future doses. Under normal circumstances, vaccines are deferred when a precaution is present. However, situations may arise when the benefit outweighs the risk (e.g., during a community pertussis outbreak).
- 4. Does the child have a long-term health problem with lung, heart, kidney, or metabolic disease (e.g., diabetes), asthma, a blood disorder, no spleen, complement component deficiency, a cochlear implant, or a spinal fluid leak? Is he/she on long-term aspirin therapy? [MMR, MMRV, LAIV, VAR]

A history of thrombocytopenia or thrombocytopenic purpura is a precaution to MMR and MMRV vaccines. The safety of LAIV in children and teens with lung, heart, kidney, or metabolic disease (e.g., diabetes), or a blood disorder has not been established. These conditions, including asthma in children ages 5 years and older, should be considered precautions for the use of LAIV. Children with functional or anatomic asplenia, complement deficiency, cochlear implant, or CSF leak should not receive LAIV. Children on long-term aspirin therapy should not be given LAIV; instead, they should be given IIV. Aspirin use is a precaution to VAP

- 5. If the child to be vaccinated is 2 through 4 years of age, has a healthcare provider told you that the child had wheezing or asthma in the past 12 months? [LAIV] Children ages 2 through 4 years who have had a wheezing episode within the past 12 months should not be given LAIV. Instead, these children should be given IIV.
- 6. If your child is a baby, have you ever been told that he or she has had intussusception? [Rotavirus]

Infants who have a history of intussusception (i.e., the telescoping of one portion of the intestine into another) should not be given rotavirus vaccine.

7. Has the child, a sibling, or a parent had a seizure; has the child had brain or other nervous system problem? [DTaP, Td, Tdap, IIV, LAIV, MMRV]

DTaP and Tdap are contraindicated in children who have a history of encephalopathy within 7 days following DTP/DTaP. An unstable progressive neurologic problem is a precaution to the use of DTaP and Tdap. For children with stable neurologic disorders (including seizures) unrelated to vaccination, or for children with a family history of seizures, vaccinate as usual (exception: children with a personal or family fi.e., parent or sibling) history of seizures generally should not be vaccinated with MMRV; they should receive separate MMR and VAR vaccines). A history of Guillain-Barré syndrome (GBS) is a consideration with the following: 1) Td/Tdap: if GBS has occurred within 6 weeks of a tetanus-containing vaccine and decision is made to continue vaccination, give Tdap instead of Td if no history of prior Tdap; 2) Influenza vaccine (IIV or LAIV): if GBS has occurred within 6 weeks of a prior influenza vaccination, vaccinate with IIV if at high risk for severe influenza complications.

NOTE: For summary information on contraindications and precautions to vaccines, go to the ACIP's General Best Practice Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html

 Does the child have cancer, leukemia, HIV/AIDS, or any other immune system problem? [LAIV, MMR, MMRV, RV, VAR]

Live virus vaccines (e.g., MMR, MMRV, VAR, RV, LAIV) are usually contraindicated in immuno-compromised children. However, there are exceptions. For example, MMR is recommended for asymptomatic HIV-infected children who do not have evidence of severe immuno-suppression. Likewise, VAR should be considered for HIV-infected children age 12 months through 8 years with age-specific CD4+ T-lymphocyte percentage at 15% or greater, or for children age 9 years or older with CD4+ T-lymphocyte counts of greater than or equal to 200 cell/µL. VAR should be administered (if indicated) to persons with isolated humoral immunodeficiency. Immunosuppressed children should not receive LAIV. Infants who have been diagnosed with severe combined immunodeficiency (SCID) should not be given a live virus vaccine, including RV. Other forms of immunosuppression are a precaution, not a contraindication, to RV. For details, consult ACIP recommendations (see references in Notes above).

 Does the child have a parent, brother, or sister with an immune system problem? [MMR. MMRV, VAR]

MMR, VAR, and MMRV vaccines should not be given to a child or teen with a family history of congenital or hereditary immunodeficiency in first-degree relatives (i.e., parents, siblings) unless the immune competence of the potential vaccine recipient has been clinically substantiated or verified by a laboratory.

10. In the past 3 months, has the child taken medications that affect the immune system such as prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis, Crohn's disease, or psoriasis; or had radiation treatments? [LAIV, MMR, MMRV, VAR]

Live virus vaccines (e.g., LAIV, MMR, MMRV, VAR) should be postponed until after chemotherapy or long-term high-dose steroid therapy has ended. For details and length of time to postpone, consult the ACIP statement. Some immune mediator and immune modulator drugs (especially the antitumor-necrosis factor agents adalimumab, infliximab, and etanercept) may be immunosuppressive. A comprehensive list of immunosuppressive immune modulators is available in CDC Health Information for International Travel (the "Yellow Book") available at wwwnc.cdc.gov/travel/yellowbook/2020/travelers-with-additional-considerations/immunocompromised-travelers. The use of live vaccines should be avoided in persons taking these drugs. To find specific vaccination schedules for stem cell transplant (bone marrow transplant) patients, see General Best Practice Guidelines for Immunization (referenced in Notes above). LAIV, when recommended, can be given only to healthy non-pregnant people ages 2 through 49 years.

- 11. In the past year, has the child received a transfusion of blood or blood products, or been given immune (gamma) globulin or an antiviral drug? [MMR, MMRV, VAR] Certain live virus vaccines (e.g., MMR, MMRV, VAR) may need to be deferred, depending on several variables. Consult the most current ACIP recommendations (referenced in Notes above) for the most current information on intervals between antiviral drugs, immune globulin or blood product administration and live virus vaccines.
- Is the child/teen pregnant or is there a chance she could become pregnant during the next month? [HPV, IPV, LAIV, MenB, MMR, MMRV, VAR]

Live virus vaccines (e.g., MMR, MMRV, VAR, LAIV) are contraindicated one month before and during pregnancy because of the theoretical risk of virus transmission to the fetus. Sexually active young women who receive a live virus vaccine should be instructed to practice careful contraception for one month following receipt of the vaccine. On theoretical grounds, IPV and MenB should not be given during pregnancy; however, it may be given if there is a risk of exposure. IIV and Tdap are both recommended during pregnancy. HPV vaccine is not recommended during pregnancy.

 Has the child received vaccinations in the past 4 weeks? [LAIV, MMR, MMRV, VAR, yellow fever]

Children who were given either LAIV or an injectable live virus vaccine (e.g., MMR, MMRV, VAR, yellow fever) should wait 28 days before receiving another vaccination of this type (30 days for yellow fever vaccine), Inactivated vaccines may be given at the same time or at any spacing interval.

## VACCINE ABBREVIATIONS

LAIV = Live attenuated influenza vaccine HPV = Human papillomavirus vaccine IIV = Inactivated influenza vaccine IPV = Inactivated poliovirus vaccine MMR = Measles, mumps, and rubella vaccine MMRV = MMR+VAR vaccine RIV = Recombinant influenza vaccine RV = Rotavirus vaccine Td/Tdap = Tetanus, diphtheria, (acellular pertussis) vaccine VAR = Varicella vaccine